Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer.

Yoichi Aoki Kazunori OchiaiSoyi LimDaisuke AokiShoji KamiuraHao LinNoriyuki KatsumataSoon-Do ChaJae-Hoon KimByoung-Gie KimYasuyuki HirashimaKeiichi FujiwaraYoung-Tak KimSeok Mo KimHyun Hoon ChungTing-Chang ChangToshiharu KamuraKen TakizawaMasahiro TakeuchiSoon-Beom Kang

Published in: British journal of cancer (2018)

S-1 plus cisplatin did not show superiority over cisplatin alone in OS but significantly increased PFS in patients with stage IVB, recurrent, or persistent cervical cancer. Since the standard therapy has changed in the course of this study, further studies are warranted to confirm the clinical positioning of S-1 combined with cisplatin for this population.

Keyphrases

phase iii
open label
stem cells
mesenchymal stem cells
study protocol
cell therapy
case control
replacement therapy